Key result
Postoperative rHu-EPO cuts blood transfusions ~59% without increasing thromboembolic events after hip arthroplasty.
Why the study?
The efficiency and safety of recombinant human erythropoietin in improving anemia and its impact on thrombotic events after total hip arthroplasty remain controversial.
Does subcutaneous administration of recombinant human erythropoietin increase thrombotic events in patients undergoing total hip arthroplasty?
RCT (n=152)
Computer-generated random sequence
No
Does subcutaneous administration of recombinant human erythropoietin increase thrombotic events in patients undergoing total hip arthroplasty?
Postoperative subcutaneous rHu-EPO in total hip arthroplasty reduces the need for allogeneic blood transfusions without increasing short-term thrombotic events.
Answers are grounded in this paper and cite their sources.
Supports postoperative rHu-EPO to reduce transfusions in hip arthroplasty; confirms short-term thromboembolic safety in this RCT.
BACKGROUND: Anemia is one of severe complications in the perioperative period of total hip arthroplasty (THA). Erythropoietin (EPO) has been considered to improve patients' anemia state, but its efficiency and safety remains controversial. METHODS: A total of 152 patients who underwent total hip arthroplasty from January 2017 to March 2019 were randomized to 2 groups. Recombinant human erythropoietin (rHu-EPO) group was treated with rHu-EPO subcutaneous injection 10000 IU after operation and once daily in the next week, while control group was treated with none extra treatment. Routine hematologic examination and thrombelastography (TEG) performed at different time point respectively. Doppler ultrasound for bilateral lower limbs was performed 1 day before surgery and 7 days after surgery. Auxiliary examination outcomes, blood transfusions outcomes, and postoperative complications were recorded as assessment indicators. RESULTS: The difference in the relevant indexes of traditional coagulation and TEG values between two groups were not significantly. No significant difference was observed in the incidence of thromboembolism events and other complications between two groups during postoperative period. The amount of intraoperative blood loss was similar between the two groups. However, the postoperative use and dosage of allogeneic blood in the rHu-EPO group were lower than those in the control group. The hemoglobin and hematocrit level in the rHu-EPO group were higher than that in the control group after surgery. CONCLUSION: Postoperative subcutaneous injection of rHu-EPO can improve hematological anemia-related parameters, reduce the use and dosage of allogeneic blood transfusions (ABTs), and has no significant influence on the formation of thrombosis and other complications in patients undergoing total hip arthroplasty in short term.
No takes yet. Share an insight, caveat, or question.
Ruan et al. (2020) conducted an RCT in Total hip arthroplasty (n=152). Recombinant human erythropoietin (rHu-EPO) vs. No extra treatment was evaluated on Thromboembolic events (p=>0.05). Postoperative subcutaneous administration of rHu-EPO reduced the need for allogeneic blood transfusions without increasing the incidence of thromboembolic events compared to control in patients undergoing total hip arthroplasty.
Synapse has enriched 10 related papers. Consider them for comparative context: